0

A Novel Tankyrase Inhibitor Decreases Canonical Wnt Signaling in Colon Carcinoma Cells and Reduces Tumor Growth in Conditional APC Mutant Mice

Jo Waaler, Ondrej Machon, Lucie Tumova, Huyen Dinh, Vladimir Korinek, Steven Ray Wilson, Jan Erik Paulsen, Nina Marie Pedersen, Tor J Eide, Olga Machonova, Dietmar Gradl, Andrey Voronkov, Jens Peter von Kries, etc.

Cancer Res. 2012 Jun 1;72(11):2822-32.

PMID: 22440753

Abstract:

Increased nuclear accumulation of β-catenin, a mediator of canonical Wnt signaling, is found in numerous tumors and is frequently associated with tumor progression and metastasis. Inhibition of Wnt/β-catenin signaling therefore is an attractive strategy for anticancer drugs. In this study, we have identified a novel small molecule inhibitor of the β-catenin signaling pathway, JW55, that functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2), regulators of the β-catenin destruction complex. Inhibition of TNKS1/2 poly(ADP-ribosyl)ation activity by JW55 led to stabilization of AXIN2, a member of the β-catenin destruction complex, followed by increased degradation of β-catenin. In a dose-dependent manner, JW55 inhibited canonical Wnt signaling in colon carcinoma cells that contained mutations in either the APC (adenomatous polyposis coli) locus or in an allele of β-catenin. In addition, JW55 reduced XWnt8-induced axis duplication in Xenopus embryos and tamoxifen-induced polyposis formation in conditional APC mutant mice. Together, our findings provide a novel chemotype for targeting canonical Wnt/β-catenin signaling through inhibiting the PARP domain of TNKS1/2.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP664993537 JW55 JW55 664993-53-7 Price
qrcode